Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof‐of‐concept, randomized, placebo‐controlled trials
Human Psychopharmacology Clinical and Experimental – February 02, 2022
Source: OpenAlex
Summary
Ayahuasca may enhance endocannabinoid levels in individuals with social anxiety disorder (SAD). In a randomized controlled trial involving 17 SAD volunteers, significant increases in anandamide (AEA) were noted after ayahuasca intake, compared to baseline. Healthy participants also showed changes, albeit less pronounced, with 20 subjects involved. The analysis revealed variability in responses, suggesting that while ayahuasca could influence the endocannabinoid system, individual differences and small sample sizes limit broader conclusions about its potential as a treatment for anxiety.
Abstract
Abstract Objective To assess endocannabinoid (anandamide, AEA; 2‐arachidonoylglycerol, 2‐AG) plasma levels in healthy volunteers and in volunteers with social anxiety disorder (SAD) after a single oral dose of ayahuasca or placebo. Methods Post hoc analysis of endocannabinoid plasma levels (baseline, 90 and 240 min after drug intake) from two parallel‐group, randomized, placebo‐controlled trials. In Study 1, 20 healthy volunteers ingested ayahuasca (average 1.58 mg/ml dimethyltryptamine (DMT)) or placebo, and in Study 2, 17 volunteers with SAD received ayahuasca (average 0.680 mg/ml DMT) or placebo. Results A significant difference was observed in AEA concentrations in Study 2 after ayahuasca intake (Χ 2 (2) = 6.5, p = 0.03, Friedman test), and near significant differences (increases) were observed between baseline and 90 (Z = 0, p = 0.06, Wilcoxon test) and 240 (Z = 10, p = 0.06) minutes after ayahuasca intake. Conclusions Although our findings suggest that ayahuasca could modulate AEA levels in SAD patients, the high interindividual variability in both trials and the small samples preclude definitive conclusions. More research with larger samples is needed to better understand the effects of ayahuasca and other hallucinogens in the endocannabinoid system.